ମଳାଶୟ କର୍କଟ
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
କେଉଁଠିକୁ ଯିବେ
ଏହି trial ପାଇଁ ଭାରତର 8ଟି hospital ପିଲାମାନଙ୍କୁ ନେଉଛି।
ରେଜିଷ୍ଟ୍ରି ସାରାଂଶ (ଟେକ୍ନିକାଲ୍)
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectabl…
ସ୍ପନସର: ଜାନସେନ ରିସର୍ଚ୍ଚ ଆଣ୍ଡ ଡେଭଲପମେଣ୍ଟ, LLC
ClinicalTrials.gov ରେ NCT06750094
ରେଜିଷ୍ଟ୍ରିରେ ଶେଷ ଅପଡେଟ୍ 25 Sep 2026 · ଆମେ ପଢ଼ିଲୁ 20 Oct 2026